Identifying the optimal dose of ritonavir in the treatment of malignancies.
about
Data to establish the optimal standard regimen and predicting the response to docetaxel therapyCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
P2860
Identifying the optimal dose of ritonavir in the treatment of malignancies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@en
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@nl
type
label
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@en
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@nl
prefLabel
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@en
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@nl
P2860
P1476
Identifying the optimal dose of ritonavir in the treatment of malignancies.
@en
P2093
Emad Y Moawad
P2860
P2888
P304
P356
10.1007/S11011-013-9448-5
P577
2013-11-19T00:00:00Z